Analysts Anticipate BioDelivery Sciences International, Inc. (BDSI) Will Post Earnings of -$0.08 Per Share

Share on StockTwits

Brokerages predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will announce earnings per share (EPS) of ($0.08) for the current quarter, according to Zacks. Five analysts have issued estimates for BioDelivery Sciences International’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.06). BioDelivery Sciences International posted earnings per share of ($0.18) in the same quarter last year, which would suggest a positive year over year growth rate of 55.6%. The business is scheduled to report its next quarterly earnings report on Thursday, May 9th.

According to Zacks, analysts expect that BioDelivery Sciences International will report full-year earnings of ($0.23) per share for the current financial year, with EPS estimates ranging from ($0.51) to ($0.12). For the next year, analysts expect that the business will report earnings of $0.18 per share, with EPS estimates ranging from $0.09 to $0.31. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.10). BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. The business had revenue of $18.03 million during the quarter, compared to analysts’ expectations of $16.15 million.

Several research firms have commented on BDSI. Cantor Fitzgerald set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, December 27th. BidaskClub raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, January 11th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 11th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and issued a $5.00 target price on shares of BioDelivery Sciences International in a research note on Thursday, January 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. BioDelivery Sciences International currently has an average rating of “Buy” and a consensus price target of $5.79.

In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction on Friday, February 1st. The shares were sold at an average price of $4.60, for a total transaction of $36,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Francis E. Odonnell, Jr. sold 23,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $5.07, for a total transaction of $116,610.00. Following the sale, the director now directly owns 544,187 shares of the company’s stock, valued at $2,759,028.09. The disclosure for this sale can be found here. Insiders have sold a total of 2,048,050 shares of company stock valued at $10,241,990 over the last three months. Corporate insiders own 13.26% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in BDSI. Stonepine Capital Management LLC grew its stake in shares of BioDelivery Sciences International by 190.1% during the 3rd quarter. Stonepine Capital Management LLC now owns 4,311,103 shares of the specialty pharmaceutical company’s stock valued at $12,071,000 after buying an additional 2,825,101 shares during the period. Nantahala Capital Management LLC grew its stake in shares of BioDelivery Sciences International by 64.0% during the 4th quarter. Nantahala Capital Management LLC now owns 2,733,567 shares of the specialty pharmaceutical company’s stock valued at $10,114,000 after buying an additional 1,066,900 shares during the period. Point72 Asset Management L.P. grew its stake in shares of BioDelivery Sciences International by 150.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,000 shares of the specialty pharmaceutical company’s stock valued at $4,200,000 after buying an additional 900,000 shares during the period. Millennium Management LLC grew its stake in shares of BioDelivery Sciences International by 703.6% during the 4th quarter. Millennium Management LLC now owns 981,422 shares of the specialty pharmaceutical company’s stock valued at $3,631,000 after buying an additional 859,292 shares during the period. Finally, Pura Vida Investments LLC purchased a new stake in shares of BioDelivery Sciences International during the 4th quarter valued at $2,305,000. 57.09% of the stock is owned by institutional investors.

Shares of BDSI traded down $0.34 during mid-day trading on Friday, reaching $4.51. 30,244 shares of the company’s stock were exchanged, compared to its average volume of 1,096,591. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82. BioDelivery Sciences International has a 52-week low of $1.70 and a 52-week high of $5.37. The stock has a market cap of $341.28 million, a price-to-earnings ratio of -6.18 and a beta of 0.46.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Further Reading: What are Institutional Investors?

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Precision Drilling Corp  Receives Average Recommendation of “Buy” from Analysts
Precision Drilling Corp Receives Average Recommendation of “Buy” from Analysts
Alphabet Inc  Receives $1,324.41 Consensus PT from Analysts
Alphabet Inc Receives $1,324.41 Consensus PT from Analysts
Burberry Group plc  Given Average Rating of “Hold” by Analysts
Burberry Group plc Given Average Rating of “Hold” by Analysts
Centuria Metropolitan REIT Plans Final Dividend of $0.04
Centuria Metropolitan REIT Plans Final Dividend of $0.04
Mullen Group Ltd to Issue Monthly Dividend of $0.05
Mullen Group Ltd to Issue Monthly Dividend of $0.05
Australian Governance & Ethical Index Fd  Announces $0.05 Final Dividend
Australian Governance & Ethical Index Fd Announces $0.05 Final Dividend


 
© 2006-2019 Zolmax.